Literature DB >> 21477669

Recombinant antibody libraries and selection technologies.

Heyue Zhou1, Yan-Liang Zhang, Guodi Lu, Henry Ji, Charles P Rodi.   

Abstract

Active immunization has benefited human health perhaps more than any other biomedical advancement. Today, passive immunization is profoundly changing the practice of medicine by enabling antibody targeting of toxic, self, and other antigens not conducive to active immunization. Recombinant antibody libraries have contributed greatly to this progress and will continue to do so. The ability to construct and display a variety of antibody libraries, including naive, immune, semi-synthetic, and synthetic ones coupled with rapid screening and selection technologies, is in large measure responsible for the thousands of monoclonal antibody therapeutics in development.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21477669     DOI: 10.1016/j.nbt.2011.03.013

Source DB:  PubMed          Journal:  N Biotechnol        ISSN: 1871-6784            Impact factor:   5.079


  8 in total

Review 1.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

2.  An automated immunoassay for early specificity profiling of antibodies.

Authors:  Katrin Frese; Meike Eisenmann; Ralf Ostendorp; Bodo Brocks; Stefan Pabst
Journal:  MAbs       Date:  2013-02-14       Impact factor: 5.857

3.  A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells.

Authors:  Youg R Thaker; Ianne Rivera; Christophe Pedros; Alok R Singh; Laura Rivero-Nava; Heyue Zhou; Barbara A Swanson; Lisa Kerwin; Yanliang Zhang; J Dixon Gray; Gunnar F Kaufmann; Henry Ji; Robert D Allen; Damien Bresson
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

4.  A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.

Authors:  Abhinav Tiwari; Marion Kasaian; Anne C Heatherington; Hannah M Jones; Fei Hua
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

Review 5.  Combinatorial approaches for the identification of brain drug delivery targets.

Authors:  Charles C Stutz; Xiaobin Zhang; Eric V Shusta
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.

Authors:  Seulki Cho; Insoo Park; Haejung Kim; Mun Sik Jeong; Mooney Lim; Eung Suk Lee; Jin Hong Kim; Semi Kim; Hyo Jeong Hong
Journal:  MAbs       Date:  2016-01-19       Impact factor: 5.857

7.  Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies.

Authors:  Chia Chiu Lim; Patrick C Y Woo; Theam Soon Lim
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

8.  Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Authors:  Xia Cao; Junki Maruyama; Heyue Zhou; Yanwen Fu; Lisa Kerwin; Colin Powers; Rachel A Sattler; John T Manning; Alok Singh; Reyna Lim; Laura D Healy; Sachi Johnson; Elizabeth Paz Cabral; Donghui Li; Lucy Lu; Arthur Ledesma; Daniel Lee; Susan Richards; Laura Rivero-Nava; Yan Li; Weiqun Shen; Karen Stegman; Benjamin Blair; Shinji Urata; Magumi Kishimoto-Urata; Jamie Ko; Na Du; Kyndal Morais; Kate Lawrence; Ianne Rivera; Chin-I Pai; Damien Bresson; Mark Brunswick; Yanliang Zhang; Henry Ji; Slobodan Paessler; Robert D Allen
Journal:  Sci Rep       Date:  2022-09-15       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.